What shapes your results
Timing changes the arithmetic of hormone therapy benefits more than any other variable. In the WHI, absolute excess adverse events on estrogen plus progestin ranged from 12 per 10,000 women per year at ages 50 to 59 up to 38 at ages 70 to 79. For estrogen alone, women aged 50 to 59 had 19 fewer events per 10,000 than placebo, while women aged 70 to 79 had 51 more. Same drugs, opposite hormone replacement outcomes, decided by when you start.
Route matters nearly as much. A matched cohort of 27,018 women in each arm found that transdermal estradiol users had a 30% lower incidence of venous thromboembolism than oral estrogen-only users, and the difference held at high doses. The biology is straightforward: skin absorption bypasses first-pass liver metabolism, so clotting factors move less.
Anatomy and history set the rest of the calculation. A uterus means you need a progestogen with systemic estrogen. Prior breast or prostate cancer and prior clots each shift the balance. Fertility plans change the answer entirely for men, and a hematocrit above 50% is a relative contraindication to starting testosterone in the first place.
Risks and alternatives
The WHI numbers give the clearest picture of systemic risk. Per 10,000 person-years on estrogen plus progestin, there were 7 more coronary events and 8 more strokes. There were also 8 more pulmonary emboli and 8 more invasive breast cancers, against 6 fewer colorectal cancers and 5 fewer hip fractures. Those are small absolute numbers that still count when a woman is weighing them against hormone therapy benefits for her own symptoms.
Testosterone carries a different set. The FDA's 2025 review confirmed that ambulatory blood pressure studies showed increased blood pressure class-wide across all testosterone products, with oral and subcutaneous formulations raising systolic pressure by roughly 4 mm Hg. Erythrocytosis is the most common lab change, and injectable formulations carry substantially higher risk than transdermal ones. In TRAVERSE, pulmonary embolism occurred in 0.9% of the testosterone arm versus 0.5% on placebo.
Fertility, Risks, and Alternatives to Hormone Therapy
Fertility suppression is the risk left out of the consultation. Testosterone acts as a contraceptive, which causes azoospermia in 65% of normospermic men within four months. Recovery happens for most men after stopping, at a median of about 110 days, but some take up to two years. If you want children in the near term, this is a reason not to start.
The alternatives are real medicine. Fezolinetant, approved by the FDA in May 2023 as a nonhormonal NK3 receptor antagonist, reduced moderate-to-severe hot flashes in the SKYLIGHT trials, though it now carries a boxed warning after the FDA identified rare serious liver injury and requires liver testing every three months for the first nine months. SSRIs and SNRIs help vasomotor symptoms and mood together. Vaginal DHEA and oral ospemifene treat genitourinary symptoms without systemic estrogen and without the systemic benefits of HRT. Resistance training and weight reduction move body composition and sexual function in men whose hormones are normal.
Reassessment and monitoring
Response timelines differ by symptom, so judging treatment too early or too late both cause problems. Hot flashes respond within weeks. Vaginal tissue changes take longer. Bone density needs one to two years before a repeat scan means anything, which is why the Endocrine Society recommends that interval for hypogonadal men with osteoporosis.
For testosterone, the schedule is well defined. Get baseline hematocrit and prostate-specific antigen (PSA) before starting. Then hematocrit and testosterone at 3, 6, and 12 months. Continue annually after that. Aim for mid-normal range concentrations. If hematocrit passes 54%, therapy stops until it comes down, and it restarts at a lower dose or a different route.
For menopausal therapy, the follow-up is more clinical than laboratory. Symptom relief is the endpoint, so the questions are whether hot flashes and sleep improved and whether there's unscheduled bleeding. Any abnormal bleeding gets investigated.
Reasons to change or stop include a new clot and the simple absence of hormone therapy benefits after an adequate trial. That last one deserves more respect than it gets. Continuing a drug that isn't working because stopping feels like giving up is how people end up on therapy for years without knowing why.
Clinician discussion checklist
Bring these questions about hormone therapy benefits to the appointment, and notice which ones get a specific answer:
-
What is my diagnosis, and which test results support it? For testosterone, were there two early-morning fasting measurements from a standardized assay?
-
Which of my symptoms do you expect to improve, and which do you expect won't? What else could be causing the ones that won't?
-
What nonhormonal or local options fit my symptom pattern, and why are we choosing this route and dose over those?
-
Do I have contraindications, given my clotting history and cancer history?
-
What happens to my fertility on this treatment, and what would we do if I wanted children?
-
What is the monitoring schedule, and which warning signs mean I should call?
-
How long before we decide this is working, and what would tell us to stop?
If a clinic can't answer the diagnosis question with specific test values, the rest of the plan rests on nothing. That's the single most useful filter you have.
Get a personalized assessment
Realistic hormone therapy benefits come from a confirmed diagnosis and follow-up labs that catch problems early. TNT Wellness in Charlotte offers physician-led hormone evaluation with blood and urine testing, plus bioidentical hormone replacement therapy and follow-up monitoring through its men's and women's hormone optimization programs. Book a hormone assessment to have your symptoms and labs evaluated together instead of guessing from symptoms alone.